Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Breast cancer, Kisqali
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence.
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence.
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
FDA Expands Approval Of Breast Cancer Drug Kisqali To Earlier-stage Patients
Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday.
The American Journal of Managed Care
4d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved
ribociclib
(Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early
breast
cancer
. The FDA approved
ribociclib
(Kisqali) with an aromatase ...
Targeted Oncology
3d
Ribociclib-Based Therapy Extends Survival in HR+/HER2– Breast Cancer
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Secret Service admits failure
Released after guilty plea
Accepts CNN debate invite
J&J unit files for bankruptcy
Sesame Place suit verdict
Rallies in North Carolina
Russia threatens retaliation
$230 million crypto theft
ISR strike on Gaza school
Feds subpoena Schaeffer
Pandas leaving for China
TN abortion law blocked
Beirut strike death toll
Drug price challenge revived
Hand count approved in GA
Top Hezbollah leader killed?
Bill to boost security OK'd
In-person voting begins
Boeing defense chief exits
Baby powder recalled
WI high court to decide
SC 1st execution in 13 years
Disney to stop using Slack
Sues pharmacy middlemen
House repeals emission rules
144K+ Mavericks recalled
FDA approves flu vaccine
Stein's ballot bid rejected
Recalling 449K+ vehicles
1st rabies outbreak in seals
Hiker injured in bear attack
Feedback